ARCHIVE REPORT

We used AI for action figures. They used it on cancer.

Merck and Moderna say their personalised cancer therapy passed a Phase 3 trial. A machine learning model picks up to 34 targets from a patient's own tumour, and those go into mRNA...

Published August 19, 2026 · AI · Science

#AI #cancer #mRNA #lilmeme

Read the original caption

Merck and Moderna say their personalised cancer therapy passed a Phase 3 trial. A machine learning model picks up to 34 targets from a patient's own tumour, and those go into mRNA so the immune system knows what to hunt. The companies released no efficacy numbers; those come later at a medical meeting. Not medical advice - the therapy is investigational.

The real news

The story, straight

Merck and Moderna said their personalized cancer therapy met the Phase 3 trial endpoints. A machine-learning model picks up to 34 targets from a patient's own tumour, and those targets go into an mRNA vaccine so the immune system knows what to hunt.

The efficacy numbers will come later at a medical meeting; the therapy is investigational.

The absurd

Why this is ridiculous

The vaccine is now a 34-person search list, and the same immune system that was taught one target is being taught thirty-four. The body's 'who's who' got a personal trainer.

The breakdown

How it breaks down

The change is not the drug, it is the list. Instead of one target for everyone, the model picks 34 targets from one patient's own tumour.

The machine's job is no longer to treat; its job is to remember what to look for.

The upside

Why it could matter

The upside is that personalized oncology moved from a conference abstract to a trial readout. If the efficacy numbers hold, the lesson is that the same platform can carry a disease-specific list without being rebuilt for every disease.